Clinical trials: Acute Lymphoblastic Leukemia, Refractory
T-ALL
CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia
Patients with acute leukemia derived from T lymphocytes have the characteristics of high expression of CD7 antigen, such as acute T lymphocyte leukemia (T-ALL).CAR-T therapy is to genetically modify the patient's T lymphocytes to…
- Trial name
- NCT04785833
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
B-ALL
Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.
- Trial name
- NCT07244406
- Testing
- S1904 CD19 CAR-T
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Leukemia, B-cell
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
This is a single center, open-label ,phase 1/2 study to evaluate the safety and efficacy of targeted CD19/CD22 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19/CD22 positive Relapsed or…
- Trial name
- NCT03614858
- Testing
- CART-19/22
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT05334823
- Testing
- pCAR-19B cells
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02269579
- Testing
- CPX-351
- Where
- 5 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
This is a Phase 1/2, open-label, single arm, multicohort study to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19+ r/r B-ALL and B-NHL.
- Trial name
- NCT03743246
- Testing
- JCAR017, Lymphodepleting, Fludarabine
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 21 people
- Sponsor
- Celgene
Relapsed or Refractory Acute Lymphoblastic Leukemia
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory acute lymphoblastic leukemia.
- Trial name
- NCT04230473
- Testing
- single dose of CNCT19
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Juventas Cell Therapy Ltd.
Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory…
- Trial name
- NCT07284927
- Testing
- LV009 Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
GVHD, Adult Acute Myeloid Leukemia
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.
- Conditions
- GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01295710
- Testing
- US-ATG-F
- Where
- 28 sites in United States, Australia
- Volunteers
- 260 people
- Sponsor
- Neovii Biotech
Leukemia, Myeloid, Chronic, Anemia, Aplastic
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
The purpose of this study is to determine whether the addition of parathyroid hormone after a sequential cord blood transplant will improve engraftment, which is the ability of the transplanted stem cells to grow and to…
- Conditions
- Leukemia, Myeloid, Chronic, Anemia, Aplastic, Myelofibrosis, Lymphoma
- Trial name
- NCT00393380
- Testing
- Parathyroid Hormone (teriparatide)
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- The Emmes Company, LLC
B-cell Acute Lymphoblastic Leukemia
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045.
- Trial name
- NCT07570173
- Testing
- MK-1045, Blinatumomab, Acetaminophen
- Where
- 28 sites in Canada, Denmark and 8 more
- Volunteers
- 340 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
The purpose of this study was to evaluate the safety and tolerance of BEBT-908 for injection in the treatment of recurrent refractory malignant lymphoma, multiple myeloma and chronic lymphoblastic leukemia, and to obtain the…
- Trial name
- NCT06082596
- Testing
- BEBT-908 for injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- BeBetter Med Inc
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions: Relapsed/refractory Ph+ Acute…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Trial name
- NCT00109707
- Testing
- Nilotinib
- Where
- 101 sites in United States, Australia and 20 more
- Volunteers
- 507 people
- Sponsor
- Novartis Pharmaceuticals
B Acute Lymphoblastic Leukemia/Lymphoma
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
- Trial name
- NCT07196111
- Testing
- BAFFR CAR-T
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL.
- Conditions
- Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
- Trial name
- NCT05885464
- Testing
- BEAM-201
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Beam Therapeutics Inc.
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
- Trial name
- NCT04703192
- Testing
- Valemetostat Tosylate
- Where
- 60 sites in United States, Australia and 10 more
- Volunteers
- 155 people
- Sponsor
- Daiichi Sankyo
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02892695
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT00384228
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
This study is being done to evaluate the rate of hematological response (complete remission/complete remission with partial hematological recovery [CR/CRh*]) induced by blinatumomab in Chinese adults with relapsed/refractory…
- Trial name
- NCT03476239
- Testing
- Blinatumomab, Dexamthasone
- Where
- 23 sites in China
- Volunteers
- 121 people
- Sponsor
- Amgen
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Expanded Access Program of Ponatinib
This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available…
- Trial name
- NCT01592136
- Testing
- ponatinib
- Where
- 33 sites in United States
- Sponsor
- Ariad Pharmaceuticals